-
AstraZeneca-Daiichi Sankyo Enhertu gets USFDA Breakthrough Therapy Designation in HER2-positive early breast cancer
22 Dec 2025 12:56 GMT
… , Global Head, R&D, Daiichi Sankyo, said, “This tenth Breakthrough Therapy … -directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly …
-
Incretin Receptor Agonist, Semaglutide, as a Treatment for Alectinib-Induced Excessive Weight Gain. A Case Report
24 Dec 2025 17:16 GMT
… a single patient investigational new drug (IND) application due to ineligibility … reports personal fees from AstraZeneca, Daiichi Sankyo, Regeneron, Boehringer Ingelheim, Eli Lilly … -1 agonist treatment, and therapeutic drug monitoring of ALK+ non-small …
-
<![CDATA[Sacituzumab Govitecan Yields Fewer AEs Vs Chemotherapy in Advanced TNBC]]>
24 Dec 2025 15:26 GMT
… those who received the antibody-drug conjugate (ADC; n = … AstraZeneca, Bayer, Celcuity, Cytomx, Daiichi Sankyo, Dantari, Dignitana, Genentech/Roche … Boehringer Ingelheim, Briacell, BridgeBio, Daiichi Sankyo, Jazz Pharmaceuticals/Zymeworks, Gilead …
-
Continued Scrutiny of Genus Claims: The Written Description and Enablement Requirements for Broad and Previously Undisclosed Subgenera
23 Dec 2025 18:59 GMT
… ) claims directed to antibody-drug conjugates (ADCs) comprising a … , an ADC, manufactured by Daiichi Sankyo (Daiichi), containing a tetrapeptide … covered ADCs having a drug moiety (D) connected … linker, where “the drug moiety is intracellularly cleaved …
-
<![CDATA[Phase 3 Trial of T-DXd Initiated in HER2+ Endometrial Cancer]]>
23 Dec 2025 16:42 GMT
AstraZeneca and Daiichi Sankyo have initiated DESTINY-Endometrial02 … Late-Stage Oncology Clinical Development, Daiichi Sankyo, in a news release. … therapy via the antibody-drug conjugate (ADC) mechanism … ADC is its high drug-to-antibody ratio (approximately …
-
<![CDATA[FDA Grants Breakthrough Status to Enhertu for Some HER2+ Early Breast Cancers ]]>
23 Dec 2025 16:30 GMT
… U.S. Food and Drug Administration has granted breakthrough … from AstraZeneca.
AstraZeneca and Daiichi Sankyo’s Enhertu's … Global Head, R&D, Daiichi Sankyo, said: “This tenth breakthrough … HER2-directed DXd antibody drug conjugate, consisting of a …
-
<![CDATA[Toxicity Considerations Drive Treatment Strategies in the New Era of NSCLC Therapy]]>
23 Dec 2025 16:44 GMT
… encompass immunotherapies and new antibody-drug conjugates (ADCs) such as telisotuzumab … /4nV8h6Bf
Datroway. Prescribing information. Daiichi Sankyo; 2025. Accessed August 27, 2025 …
-
AZN, Daiichi's Enhertu Gets FDA Nod for First-Line Breast Cancer (Revised)
23 Dec 2025 11:53 GMT
… partner Daiichi Sankyo announced that the FDA has approved their blockbuster antibody-drug … combined with Roche’s cancer drugs Herceptin and Perjeta (“THP”) … to include Datroway (datopotamab deruxtecan). Daiichi Sankyo is responsible for the manufacturing …
-
Federal Circuit Patent Watch: Disclosure of a Broad Genus Is Insufficient Written Description Support for a Subgenus of Chemical Structures Without Adequate Blaze Marks
23 Dec 2025 01:25 GMT
… 1f].
6. SEAGEN INC. v. DAIICHI SANKYO COMPANY, LTD. [OPINION] (2023- … of cancer treatment—an antibody-drug conjugate (“ADC”)—that includes … Daiichi’s Enhertu® cancer drug infringed the ’039 patent. … “an ADC containing any drug moiety with the recited function …
-
<![CDATA[T-DXd Granted Breakthrough Therapy Designation in Post-Neoadjuvant HER2-Positive Early Breast Cancer]]>
22 Dec 2025 20:45 GMT
… (T-DXd, Enhertu; Daiichi Sankyo, Inc., AstraZeneca), an antibody-drug conjugate (ADC), has …
About
© 1995-2025